What's in a Name? Moving to Neuroscience-Based Nomenclature in Pediatric Psychopharmacology.
What's in a Name? Moving to Neuroscience-Based Nomenclature in Pediatric Psychopharmacology.
复制标题
名字里有什么？
DOI：
10.1016/j.jaac.2018.05.024
复制
发表时间：
2018
影响因子：
13.3
通讯作者：
Veenstra-VanderWeele,Jeremy
中科院分区：
文献类型：
--
作者：
Sultan,RyanS;Correll,ChristophU;Zohar,Joseph;Zalsman,Gil;Veenstra-VanderWeele,Jeremy
我们对精神药物类别的传统名称导致了不必要的混淆。作为临床医生，我们已经习惯了精神药物的特殊名称，忘记了它们是多么不清楚和具有误导性。例如，有证据表明，5-羟色胺再摄取抑制剂对儿童焦虑症有帮助，但有焦虑孩子的父母可能会问，如果你诊断我的儿子患有分离焦虑症，为什么要给他抗抑郁药？另一位家长可能会反对使用“兴奋剂”药物，“我女儿从不放慢脚步，她最不需要的就是兴奋剂！”类似地，可以在标签上给患有躁狂症、双相抑郁、抽搐或自闭症易怒的年轻人开“抗精神病药物”，但家人和患者可能会对“精神病”的隐含标签感到困惑或反对。此外，患者或家属可以
Our traditional names for psychotropic medication classes lead to unnecessary confusion. As clinicians, we have grown comfortable with idiosyncratic names of psychotropic medications and forgotten how unclear and misleading they can be. For example, evidence shows that serotonin reuptake inhibitors help in pediatric anxiety disorders, but a parent with an anxious child might ask,“If you diagnosed my son with separation anxiety, why are you giving him an antidepressant?” Another parent might object to the use of a “stimulant” medication,“My daughter never slows down, the last thing she needs is a stimulant!” Similarly, an “antipsychotic” can be prescribed on-label to youth with mania, bipolar depression, tics, or irritability in autism but families and patients might be confused by or object to the implied label of being “psychotic”. Further, patients or family members may